These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19154503)

  • 1. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.
    Gazzaniga P; Gradilone A; de Berardinis E; Sciarra A; Cristini C; Naso G; di Silverio F; Frati L; Aglianò AM
    BJU Int; 2009 Jul; 104(2):184-8. PubMed ID: 19154503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravesical therapy: Influence on superficial bladder cancer progression].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.
    Whitson J; Berry A; Carroll P; Konety B
    BJU Int; 2009 Aug; 104(3):336-9. PubMed ID: 19220253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.
    Kipp BR; Karnes RJ; Brankley SM; Harwood AR; Pankratz VS; Sebo TJ; Blute MM; Lieber MM; Zincke H; Halling KC
    J Urol; 2005 Feb; 173(2):401-4. PubMed ID: 15643180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
    Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
    Karakiewicz PI; Benayoun S; Lewinshtein DJ; Chun FK; Shahrour K; Perrotte P
    Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 14. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
    Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
    Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
    Horvath A; Mostafid H
    BJU Int; 2009 Mar; 103(6):726-9. PubMed ID: 19007379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
    Descazeaud A; Mignard JP; Davin JL; Irani J
    Prog Urol; 2009 Oct; 19(9):624-31. PubMed ID: 19800553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.